FutraMed

Executive Summary

FutraMed is a private San Diego-based medical device company developing Transcutaneous Cranial Electrical Stimulation (TCES) technology for the treatment of opioid withdrawal symptoms. Founded in 2018, the company aims to address the growing opioid addiction crisis with a non-invasive, painless neurostimulation approach. TCES delivers balanced current pulses to specific cranial areas to alleviate withdrawal symptoms, offering a potential alternative or adjunct to medication-assisted treatments. The technology targets the autonomic nervous system to reduce cravings and discomfort, with the goal of improving outcomes for patients seeking recovery. While still in early stages with no disclosed funding or size, FutraMed operates in a high-need area of drug delivery and dermatology, though its core focus remains addiction medicine. The company's stage is not publicly specified, suggesting pre-clinical or early clinical development. With limited public information, the company has low profile visibility but significant potential if TCES proves effective in human trials.

Upcoming Catalysts (preview)

• Q4 2026Announcement of first clinical trial results for TCES in opioid withdrawal50% success
• Q1 2027Partnership with a major addiction treatment center or hospital network30% success
• Q2 2027FDA breakthrough device designation or expedited regulatory pathway40% success